414 related articles for article (PubMed ID: 19944595)
1. 18FDG-PET-CT in the follow-up of non-small cell lung cancer patients after radical radiotherapy with or without chemotherapy: an economic evaluation.
van Loon J; Grutters JP; Wanders R; Boersma L; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Brans B; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
Eur J Cancer; 2010 Jan; 46(1):110-9. PubMed ID: 19944595
[TBL] [Abstract][Full Text] [Related]
2. Follow-up with 18FDG-PET-CT after radical radiotherapy with or without chemotherapy allows the detection of potentially curable progressive disease in non-small cell lung cancer patients: a prospective study.
van Loon J; Grutters J; Wanders R; Boersma L; Oellers M; Dingemans AM; Bootsma G; Geraedts W; Pitz C; Simons J; Fatah SA; Snoep G; Hochstenbag M; Lambin P; De Ruysscher D
Eur J Cancer; 2009 Mar; 45(4):588-95. PubMed ID: 19046631
[TBL] [Abstract][Full Text] [Related]
3. Is FDG PET/CT cost-effective for pre-operation staging of potentially operative non-small cell lung cancer? - From Chinese healthcare system perspective.
Wang YT; Huang G
Eur J Radiol; 2012 Aug; 81(8):e903-9. PubMed ID: 22698711
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness analysis of routine surveillance imaging of patients with diffuse large B-cell lymphoma in first remission.
Huntington SF; Svoboda J; Doshi JA
J Clin Oncol; 2015 May; 33(13):1467-74. PubMed ID: 25823735
[TBL] [Abstract][Full Text] [Related]
5. Should mediastinoscopy actually be incorporated into the FDG PET strategy for patients with non-small cell lung carcinoma?
Hayashi K; Abe K; Yano F; Watanabe S; Iwasaki Y; Kosuda S
Ann Nucl Med; 2005 Jul; 19(5):393-8. PubMed ID: 16164196
[TBL] [Abstract][Full Text] [Related]
6. Cost-effectiveness of hybrid PET/CT for staging of non-small cell lung cancer.
Schreyögg J; Weller J; Stargardt T; Herrmann K; Bluemel C; Dechow T; Glatting G; Krause BJ; Mottaghy F; Reske SN; Buck AK
J Nucl Med; 2010 Nov; 51(11):1668-75. PubMed ID: 21051648
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness analysis of 18F-FDG PET/CT in detecting suspected recurrence or metastasis in well-differentiated thyroid carcinoma patients with negative diagnostic total body scan in Thailand: a decision analysis.
Khiewvan B; Nopmaneejumruslers C; Pusuwan P; Tuchinda P; Tojinda N; Ubolnuch K
J Med Assoc Thai; 2013 Oct; 96(10):1350-64. PubMed ID: 24350419
[TBL] [Abstract][Full Text] [Related]
8. Individualized positron emission tomography-based isotoxic accelerated radiation therapy is cost-effective compared with conventional radiation therapy: a model-based evaluation.
Bongers ML; Coupé VM; De Ruysscher D; Oberije C; Lambin P; Uyl-de Groot CA
Int J Radiat Oncol Biol Phys; 2015 Mar; 91(4):857-65. PubMed ID: 25752401
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness analysis in the clinical management of patients with known or suspected lung cancer: [18F]fluorodeoxyglucose PET and CT comparison.
Mansueto M; Grimaldi A; Torbica A; Pepe G; Giovacchini G; Messa C; Fazio F
Q J Nucl Med Mol Imaging; 2007 Sep; 51(3):224-34. PubMed ID: 17538525
[TBL] [Abstract][Full Text] [Related]
10. Cost-effectiveness analysis of strategies introducing integrated ¹⁸F-FDG PET/CT into the mediastinal lymph node staging of non-small-cell lung cancer.
Han Y; Xiao H; Zhou Z; Yuan M; Zeng Y; Wu H; Fang Y
Nucl Med Commun; 2015 Mar; 36(3):234-41. PubMed ID: 25460305
[TBL] [Abstract][Full Text] [Related]
11. Decision tree sensitivity analysis for cost-effectiveness of FDG-PET in the staging and management of non-small-cell lung carcinoma.
Gambhir SS; Hoh CK; Phelps ME; Madar I; Maddahi J
J Nucl Med; 1996 Sep; 37(9):1428-36. PubMed ID: 8790186
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness of FDG-PET in staging non-small cell lung cancer: the PLUS study.
Verboom P; van Tinteren H; Hoekstra OS; Smit EF; van den Bergh JH; Schreurs AJ; Stallaert RA; van Velthoven PC; Comans EF; Diepenhorst FW; van Mourik JC; Postmus PE; Boers M; Grijseels EW; Teule GJ; Uyl-de Groot CA;
Eur J Nucl Med Mol Imaging; 2003 Nov; 30(11):1444-9. PubMed ID: 14579081
[TBL] [Abstract][Full Text] [Related]
13. Clinical value of F18-fluorodeoxyglucose positron emission tomography-computed tomography in patients with non-small cell lung cancer after potentially curative surgery: experience with 241 patients.
Kanzaki R; Higashiyama M; Maeda J; Okami J; Hosoki T; Hasegawa Y; Takami M; Kodama K
Interact Cardiovasc Thorac Surg; 2010 Jun; 10(6):1009-14. PubMed ID: 20197344
[TBL] [Abstract][Full Text] [Related]
14. Decision-tree sensitivity analysis for cost-effectiveness of chest 2-fluoro-2-D-[(18)F]fluorodeoxyglucose positron emission tomography in patients with pulmonary nodules (non-small cell lung carcinoma) in Japan.
Kosuda S; Ichihara K; Watanabe M; Kobayashi H; Kusano S
Chest; 2000 Feb; 117(2):346-53. PubMed ID: 10669673
[TBL] [Abstract][Full Text] [Related]
15. The value of FDG positron emission tomography/computerised tomography (PET/CT) in pre-operative staging of colorectal cancer: a systematic review and economic evaluation.
Brush J; Boyd K; Chappell F; Crawford F; Dozier M; Fenwick E; Glanville J; McIntosh H; Renehan A; Weller D; Dunlop M
Health Technol Assess; 2011 Sep; 15(35):1-192, iii-iv. PubMed ID: 21958472
[TBL] [Abstract][Full Text] [Related]
16. An economic evaluation of positron emission tomography (PET) and positron emission tomography/computed tomography (PET/CT) for the diagnosis of breast cancer recurrence.
Auguste P; Barton P; Hyde C; Roberts TE
Health Technol Assess; 2011 Apr; 15(18):iii-iv, 1-54. PubMed ID: 21524363
[TBL] [Abstract][Full Text] [Related]
17. Cost-effectiveness of FDG-PET for staging non-small cell lung cancer: a decision analysis.
Scott WJ; Shepherd J; Gambhir SS
Ann Thorac Surg; 1998 Dec; 66(6):1876-83; discussion 1883-5. PubMed ID: 9930463
[TBL] [Abstract][Full Text] [Related]
18. Effect of PET/CT on management of patients with non-small cell lung cancer: results of a prospective study with 5-year survival data.
Gregory DL; Hicks RJ; Hogg A; Binns DS; Shum PL; Milner A; Link E; Ball DL; Mac Manus MP
J Nucl Med; 2012 Jul; 53(7):1007-15. PubMed ID: 22677701
[TBL] [Abstract][Full Text] [Related]
19. Positron emission tomography/computerised tomography imaging in detecting and managing recurrent cervical cancer: systematic review of evidence, elicitation of subjective probabilities and economic modelling.
Meads C; Auguste P; Davenport C; Małysiak S; Sundar S; Kowalska M; Zapalska A; Guest P; Thangaratinam S; Martin-Hirsch P; Borowiack E; Barton P; Roberts T; Khan K
Health Technol Assess; 2013 Mar; 17(12):1-323. PubMed ID: 23537558
[TBL] [Abstract][Full Text] [Related]
20. Positron emission tomography with selected mediastinoscopy compared to routine mediastinoscopy offers cost and clinical outcome benefits for pre-operative staging of non-small cell lung cancer.
Yap KK; Yap KS; Byrne AJ; Berlangieri SU; Poon A; Mitchell P; Knight SR; Clarke PC; Harris A; Tauro A; Rowe CC; Scott AM
Eur J Nucl Med Mol Imaging; 2005 Sep; 32(9):1033-40. PubMed ID: 15875178
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
